Note - The COVID-19 Vaccine Group is based on the interim recommendations from ACIP. As additional guidelines are published, the COVID-19 logic in ICE will be updated. This release includes support for the following COVID-19 vaccines:
...
CVX Code | Name | Absolute Minimum Age |
|---|
| 207 | Moderna COVID-19 Vaccine | 0 days |
208 | Pfizer COVID-19 Vaccine | 0 days |
| 210 | AstraZeneca COVID-19 Vaccine | 0 days |
| 212 | Janssen COVID-19 Vaccine | 0 days |
| 213 | SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED | 0 days |
(*) If a COVID-19 vaccine is administered before the vaccine's minimum age or series' recommended age (16y - 4d for Pfizer; 18y - 4d for Moderna), or below the series' minimum interval, supplemental text is returned to alert the user of this fact even though the may have been evaluated as Valid. See "Series Special Rules" for all series below for more details. (Note: the running distribution must have the output_supplemental_text option enabled for the supplemental text to be returned.)
(*) See not about exception logic for AstraZeneca below.
Combination Vaccines that Include COVID-19
...
| Panel |
|---|
| borderColor | #CCFFFF |
|---|
| bgColor | #CCFFFF |
|---|
| titleBGColor | #99FFFF |
|---|
| borderStyle | solid |
|---|
|
CVX Code Specific RulesCVX Code Absolute Minimum AgeRule for CVX 213- If the patient receives CVX 213 for:
- Target Dose 1, evaluate the shot as Valid.
- Recommend Target Dose 2 at Vaccine Group level
- Recommended interval = 28 days
- Recommended age = 18 years
- Target Dose 2, evaluate the shot as Valid.
- If the patient receives CVX 213 for Target Dose 1 and CVX 212 (Janssen COVID-19 Vaccine) is reported for Target Dose 2, the Janssen COVID-19 1-dose Series applies and the series is complete. Therefore,
- evaluate Target Dose 2 (CVX 212) as Valid
- evaluate Target Dose 1 as Accepted and the reason code is VACCINE_NOT_COUNTED_BASED_ON_MOST_RECENT_VACCINE_GIVEN.
- If the patient receives CVX 213 for Target Dose 1 and CVX 210 (AstraZeneca COVID-19 Vaccine) for Target Dose 2 or CVX 210 (AstraZeneca COVID-19 Vaccine) for Target Dose 1 and CVX 213 for Target Dose 2, then:
- evaluate both shots as Valid.
- No additional doses of COVID-19 vaccine are needed; Recommendation: Not Recommended/ COMPLETE.
Rule for CVX 210 (AstraZeneca COVID-19 Vaccine)1- If the patient has received CVX 210 (AstraZeneca COVID-19 vaccine) for Target Dose 1 and Target Dose 2, then:
- Evaluate both shots as Valid.
- No additional doses of COVID-19 vaccine are needed; Recommendation: Not Recommended/ COMPLETE.
- If the patient has received CVX 210 (AstraZeneca COVID-19 vaccine) for Target Dose 1 only, then:
- Evaluate the shot as Accepted/ VACCINE_NOT_APPROVED_IN_US. (new reason code)
- Recommendation:
- If CVX 210 is the last COVID-19 shot administered, then recommend COVID-19 at the vaccine group level at last shot administered + recommended interval (28 days).
- Example #1: Patient has 1 shot of CVX 210 (AstraZeneca) on record.
- Evaluate CVX 210 as Accepted/ VACCINE_NOT_APPROVED_IN_US.
- Recommend COVID-19 at the vaccine group level at CVX 210 + recommended interval (28 days).
- Example #2: Patient has 1 shot of CVX 208 (Pfizer), then 1 shot of CVX 210 (AstraZeneca) on record.
- Evaluate CVX 208 as Valid and CVX 210 as Accepted/ VACCINE_NOT_APPROVED_IN_US.
- Recommend COVID-19 at the vaccine group level at CVX 210 + recommended interval (28 days).
- If CVX 210 is not the last COVID-19 shot administered, recommend based on the series that applies for the last COVID-19 shot administered.
- Example: If CVX 208 (Pfizer) is given after CVX 210 (AstraZeneca), then recommend based on the Pfizer COVID-19 2-dose Series.
|
| Panel |
|---|
| borderColor | #FDF5E6 |
|---|
| bgColor | #FDF5E6 |
|---|
| titleBGColor | #FAEBD7 |
|---|
| borderStyle | solid |
|---|
|
Notes- 1CVX 210 (AstraZeneca COVID-19 Vaccine) has not yet been approved for use in the U.S. by the FDA, but it is approved by the WHO. The following ICE "Rule for CVX 210 (AstraZeneca COVID-19 Vaccine)" rules were created to handle AstraZeneca shots reported on patient records. The ICE rules were created and sourced from published guidance from the CDC, updated April 27, 2021 - Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States. When the FDA approves the AstraZeneca COVID-19 vaccine (CVX 210) for use in the U.S., ICE will be updated as necessary.
|
...
Dose | Series Name | Absolute Minimum
Age | Minimum Age | Routine
Age | Latest Recommended Age (less than) | Valid CVX Code(s) per Dose for this Series | Invalid CVX Code(s) per Dose for this Series |
|---|
1 | Moderna COVID-19 2-dose Series | 0 days | 18 years | 18 years | N/A | 207, 213 | N/A
|
2 | Moderna COVID-19 2-dose Series | 0 days | 18 years | 18 years | N/A | 207, 208, 213 | N/A
|
...
Doses | Series Name | Absolute Minimum Interval | Minimum Interval | Recommended Interval | Latest Recommended Interval (less than) |
|---|
Dose 1 to 2 | Moderna COVID-19 2-dose Series | 0 days | 28 days | 28 days | N/A |
...